The University of Southampton
University of Southampton Institutional Repository

Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand

Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand
Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand
The United Kingdom, Australia and New Zealand use different criteria for public funding of pharmaceuticals, but all include estimates of clinical effectiveness and cost-effectiveness.

Drug appraisal is done through the National Institute for Health and Clinical Excellence (NICE) in the UK, the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia, and the Pharmaceutical Management Agency (PHARMAC) in NZ.

Of the 10 drugs deemed least cost-effective by NICE between 1996 and 2005, all were approved for funding in the UK, six were approved in Australia and five were approved in NZ.

Australia and NZ refused funding for drugs for obesity, influenza and growth deficiency.

All three countries made exceptions in order to fund drugs of poor cost-effectiveness for some “dread” diseases, but some drugs for less alarming conditions were either not funded or heavily restricted.


0025-729x
26-28
Raftery, James P.
27c2661d-6c4f-448a-bf36-9a89ec72bd6b
Raftery, James P.
27c2661d-6c4f-448a-bf36-9a89ec72bd6b

Raftery, James P. (2008) Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand. Medical Journal of Australia, 188 (1), 26-28. (PMID:18205559)

Record type: Article

Abstract

The United Kingdom, Australia and New Zealand use different criteria for public funding of pharmaceuticals, but all include estimates of clinical effectiveness and cost-effectiveness.

Drug appraisal is done through the National Institute for Health and Clinical Excellence (NICE) in the UK, the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia, and the Pharmaceutical Management Agency (PHARMAC) in NZ.

Of the 10 drugs deemed least cost-effective by NICE between 1996 and 2005, all were approved for funding in the UK, six were approved in Australia and five were approved in NZ.

Australia and NZ refused funding for drugs for obesity, influenza and growth deficiency.

All three countries made exceptions in order to fund drugs of poor cost-effectiveness for some “dread” diseases, but some drugs for less alarming conditions were either not funded or heavily restricted.


This record has no associated files available for download.

More information

Published date: 7 January 2008

Identifiers

Local EPrints ID: 183685
URI: http://eprints.soton.ac.uk/id/eprint/183685
ISSN: 0025-729x
PURE UUID: 4b4d65c9-3f49-4f6c-90c3-957ae5d6d6c7

Catalogue record

Date deposited: 04 May 2011 08:12
Last modified: 22 Jul 2022 17:40

Export record

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×